Dimethyl Sulfoxide
Apexbio Technology LLC SU11274 658084-23-2 10mM (in 1mL DMSO)
SU11274 (CAS 658084-23-2) is a selective inhibitor targeting Met kinase exhibiting an IC50 of approximately 10 nM The compound specifically suppresses the autophosphorylation of Met at residues Tyr1234/1235 disrupting receptor activity with minimal effects on other receptor tyrosine kinases such as EGFR and PDGFR or serine/threonine kinases including CDK2 In NIH3T3 cells expressing drug-sensitive or resistant MET mutants and in H1993 human lung cancer cells treatment with SU11274 induces a dose-dependent inhibition of Met phosphorylation and impairs receptor ubiquitination leading to receptor accumulation SU11274 serves as a useful tool for investigating Met signaling pathways in oncology research
Apexbio Technology LLC PF-543 1415562-82-1 10mM (in 1mL DMSO)
PF-543 (CAS 1415562-82-1) is a cell-permeable inhibitor targeting sphingosine kinase 1 (SphK1) an enzyme that phosphorylates sphingosine to sphingosine-1-phosphate (S1P) It displays potent inhibitory activity against SphK1 with an IC50 of 3 6 nM through sphingosine-competitive (non-ATP competitive) binding Treatment of SphK1-overexpressing head and neck cancer (1483) cells led to a ten-fold decrease in S1P levels confirming effective target engagement PF-543 is widely utilized as a research tool in studies investigating SphK1-mediated signaling pathways in cancer biology and immune cell trafficking
Apexbio Technology LLC AT9283 896466-04-9 10mM (in 1mL DMSO)
AT9283 (CAS 896466-04-9) is a synthetic small-molecule inhibitor developed through fragment-based drug design It inhibits Aurora kinases A and B key components of the serine/threonine kinase family involved in regulating cell division processes as well as targets including Janus kinases (JAKs) BCR-ABL kinase (including the T315I mutant) and Flt-3 With a potent IC50 around 3 nM against Aurora kinases AT9283 exhibits antiproliferative and pro-apoptotic activity in leukemia myeloproliferative diseases solid tumors and B-cell lymphoma models It is utilized primarily in cancer biology research to investigate its therapeutic potential targeting aberrant kinase activity
Medchemexpress LLC Crenigacestat 10Mm/1Ml In Dmso | HY-12449-10MM/1ML IN DMSO
Crenigacestat 10Mm/1Ml In Dmso
Apexbio Technology LLC Bay 11-7085(Synonyms: BAY-11-7085, BAY 117085, BAY117085, Bay11-7085, BAY 11 7085, BAY-117085, Bay 11 7085), 10mM (in 1mL DMSO), CAS: 196309-76-9.
Bay 11-7085 (CAS 196309-76-9) is a soluble inhibitor of nuclear factor-kappa B (NF- B) activation It inhibits cell proliferation and promotes apoptosis in various cell types through interference with NF- B signaling pathways Studies have demonstrated that Bay 11-7085 decreases DNA synthesis in endometriotic stromal cells (ECSCs) leading to cell cycle arrest at G0/G1 phase Furthermore treatment with Bay 11-7085 induces apoptosis by downregulating anti-apoptotic proteins such as Bcl-2 and Bcl-XL while enhancing activation of caspase-3 caspase-8 and caspase-9 Bay 11-7085 is commonly employed as a chemical probe in biomedical research on inflammation and apoptosis pathways
Apexbio Technology LLC GW0742 317318-84-6 10mM (in 1mL DMSO)
GW0742 is a synthetic selective agonist of peroxisome proliferator-activated receptor / (PPAR / ) a ligand-dependent transcription factor involved in regulating lipid metabolism inflammation and energy homeostasis Activation of PPAR / modulates downstream gene transcription influencing physiological processes including inflammatory responses and neuronal protection Experimental studies demonstrate GW0742 s role in attenuating inflammation-mediated tissue injury such as ischemia/reperfusion-induced intestinal damage as well as mitigating radiation-induced neuroinflammation and cognitive impairment in animal models Thus GW0742 serves as a research tool to study PPAR / specific pathways in inflammatory diseases metabolic processes and neuroprotective mechanisms
Apexbio Technology LLC VX-809 936727-05-8 10mM (in 1mL DMSO)
VX-809 (CAS 936727-05-8) is a small molecule CFTR corrector that partially restores the functional expression of F508del-CFTR the most common mutation associated with cystic fibrosis (CF) VX-809 stabilizes the misfolded CFTR protein by interacting with its membrane-spanning domain 1 (MSD1) thus facilitating proper maturation and membrane localization In F508del-CFTR-expressing Fischer rat thyroid (FRT) cells VX-809 enhanced CFTR protein processing (EC50 0 1 M) and improved chloride transport (EC50 0 5 M) VX-809 is utilized predominantly as a research tool in CF studies to understand and restore CFTR function often in combination with CFTR potentiators
Apexbio Technology LLC MC1568 852475-26-4 10mM (in 1mL DMSO)
MC1568 (CAS 852475-26-4) is a histone deacetylase (HDAC) inhibitor derived from the (aryloxopropenyl)pyrrolyl hydroxyamide chemical class It selectively targets class II HDAC enzymes particularly class IIa subtypes (HDAC4 HDAC5 HDAC7 HDAC9) inhibiting maize class II HDAC activity with an IC50 of 22 M MC1568 modulates muscle differentiation pathways by reducing MEF2D expression stabilizing HDAC-HDAC3-MEF2D complexes and preventing MEF2D acetylation in cultured myocytes It also interferes with differentiation signals mediated via RAR and PPAR nuclear receptors serving as a valuable tool in epigenetic and cellular differentiation studies
Medchemexpress LLC Cwi1-2 10 Mm - 1 Ml In Dmso | HY-153274-10MM-1ML DMSO
Cwi1-2 10 Mm - 1 Ml In Dmso
Apexbio Technology LLC Apremilast (CC-10004) 608141-41-9 10mM (in 1mL DMSO)
Apremilast (CC-10004 CAS 608141-41-9) is a small-molecule inhibitor of phosphodiesterase 4 (PDE4) an enzyme involved in cyclic adenosine monophosphate (cAMP) hydrolysis and cytokine signaling pathways By competitively binding PDE4 s catalytic domain apremilast prevents intracellular cAMP degradation (IC50 0 074 M Ki 68 nM) thereby suppressing production of inflammatory mediators such as tumor necrosis factor- interleukin-23 CXCL9 and CXCL10 Due to these anti-inflammatory effects apremilast serves as a significant research tool in autoimmune conditions notably psoriasis and psoriatic arthritis
Apexbio Technology LLC Bortezomib (PS-341) 179324-69-7 10mM (in 1mL DMSO)
Bortezomib (PS-341 CAS number 179324-69-7) is a reversible proteasome inhibitor structurally composed as an N-terminally protected dipeptide (Pyz-Phe-boroLeu) containing pyrazinoic acid phenylalanine and leucine with boronic acid substitution It exerts biological activity primarily by inhibiting proteasomal degradation pathways thereby accumulating pro-apoptotic factors and initiating programmed cell death Bortezomib inhibits proliferation in cell-based assays such as human non-small cell lung cancer H460 cells (IC50 0 1 M) It has clinical approval for relapsed multiple myeloma and mantle cell lymphoma and is widely employed in research to study proteasome-regulated cellular processes and apoptosis signaling pathways
Apexbio Technology LLC Fingolimod (FTY720) 162359-56-0 10mM (in 1mL DMSO)
Fingolimod (FTY720 CAS 162359-56-0) is an orally administered sphingosine-1-phosphate (S1P) receptor agonist structurally analogous to natural sphingosine Originally derived from fungal metabolites and initially investigated in organ transplantation fingolimod interacts potently with receptors S1P1 S1P3 S1P4 and S1P5 (EC50 values approximately 0 3 3 1 nM) Its agonism promotes receptor internalization suppressing lymphocyte migration from lymph nodes into the circulation and central nervous system (CNS) Thus fingolimod is studied primarily for autoimmune disorders especially multiple sclerosis due to its effects on lymphocyte trafficking and CNS infiltration